capreomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 3063 11003-38-6

Description:

MoleculeDescription

Synonyms:

  • capreomycin
  • capastat
  • capostatin
  • capreomicin
  • capromycin
  • capreomycin sulfate
  • capreomycine
  • capreomycine sulfate
Cyclic peptide antibiotic similar to VIOMYCIN. It is produced by Streptomyces capreolus.
  • Molecular weight: 1321.44
  • Formula: C50H88N28O15
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 378.42
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
1 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 26.61 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
June 2, 1971 FDA AKORN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 102.93 60.38 31 430 59499 63429062
Drug resistance 101.14 60.38 25 436 22908 63465653
Hepatitis B 92.49 60.38 17 444 3795 63484766

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 96.05 43.43 31 431 40921 34915548
Drug resistance 87.63 43.43 26 436 25901 34930568
Hepatotoxicity 49.06 43.43 16 446 21469 34935000
Neuropathy peripheral 48.54 43.43 23 439 83240 34873229

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 181.78 42.63 60 928 90326 79653074
Drug resistance 152.52 42.63 44 944 42169 79701231
Hepatitis B 70.02 42.63 17 971 8315 79735085
Neuropathy peripheral 69.14 42.63 34 954 141271 79602129
Optic neuropathy 61.33 42.63 13 975 3471 79739929
Hepatotoxicity 56.82 42.63 22 966 51330 79692070

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J04AB30 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Antibiotics
FDA EPC N0000175483 Antimycobacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000904 Antibiotics, Antitubercular
MeSH PA D000995 Antitubercular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011500 Protein Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute tuberculosis indication 25629007
Pulmonary tuberculosis indication 154283005 DOID:2957
Hearing loss contraindication 15188001
Dehydration contraindication 34095006
Hypokalemia contraindication 43339004
Neuromuscular block, function contraindication 55394004
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Disorder of the 8th Cranial Nerve contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4019652 VUID
N0000178639 NUI
D00135 KEGG_DRUG
4017459 VANDF
4019652 VANDF
C0262964 UMLSCUI
CHEBI:3371 CHEBI
CHEMBL2221250 ChEMBL_ID
D002207 MESH_DESCRIPTOR_UI
DB00314 DRUGBANK_ID
1145 INN_ID
1405-37-4 SECONDARY_CAS_RN
232HYX66HC UNII
3000502 PUBCHEM_CID
1987 RXNORM
4345 MMSL
d01103 MMSL
002787 NDDF
004901 NDDF
14170004 SNOMEDCT_US
387081001 SNOMEDCT_US
85580008 SNOMEDCT_US
CHEMBL2218913 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CAPASTAT SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 17478-080 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR NDA 23 sections